Market Place
Sourcing Support
J&J Discontinues 2 CAR-T Lymphoma Therapies Due To Market Changes
01 May 2026 //
ENDPOINTS
IMAAVY Shows 2-Year Control in Generalized Myasthenia Gravis
23 Apr 2026 //
GLOBENEWSWIRE
J&J hands back failed gene therapy to MeiraGTx
16 Apr 2026 //
FIERCE BIOTECH
J&J Charts Speedy Launch Of New Psoriasis Pill Icotyde
14 Apr 2026 //
FIERCE PHARMA
J&J, Royalty To Co-Fund $500M Autoimmune Antibody Program
30 Mar 2026 //
FIERCE BIOTECH
Takeda Clears Path To FDA With Phase 3 Data On $4B Psoriasis Bet
28 Mar 2026 //
FIERCE BIOTECH
ICOTYDE Shows 1-Year Efficacy & Safety in Plaque Psoriasis
28 Mar 2026 //
PR NEWSWIRE
J&J DARZALEX First Self-Admin Oncology Injectable Approved
27 Mar 2026 //
GLOBENEWSWIRE
Dizal`s Zegfrovy Adds More Pressure To J&J`s Rybrevant
23 Mar 2026 //
FIERCE PHARMA
US FDA Approves J&J`s Oral Psoriasis Pill
18 Mar 2026 //
REUTERS
Monte Rosa Therapeutics Secures Supply Deal For MRT-2359 Phase 2
16 Mar 2026 //
GLOBENEWSWIRE
J&J highlights promising first-in-human Erda-iDRS results
13 Mar 2026 //
PR NEWSWIRE
Legend Sloughs Off Carvykti Threat From J&J`s Tecvayli
12 Mar 2026 //
FIERCE PHARMA
Janssen Submits TECVAYLI to EMA for R/R Multiple Myeloma
10 Mar 2026 //
GLOBENEWSWIRE
EC approves AKEEGA for the treatment mHSPC Prostate Cancer
09 Mar 2026 //
GLOBENEWSWIRE
J&J Secures Third FDA Approval For Multiple Myeloma Treatment
07 Mar 2026 //
BIOSPACE
Johnson & Johnson Gets FDA Nod For TECVAYLI With DARZALEX
06 Mar 2026 //
PR NEWSWIRE
US FDA Approves Johnson & Johnson`s Blood Cancer Drug
05 Mar 2026 //
REUTERS
Johnson & Johnson Reports Promising Antitumor Activity
26 Feb 2026 //
PR NEWSWIRE
GSK Props Up Its Cabenuva In Adolescents With Long-Term Data
26 Feb 2026 //
FIERCE PHARMA
EC Approves SC RYBREVANT for EGFR NSCLC Cancer
24 Feb 2026 //
PHARMIWEB
Guselkumab Maintains Ulcerative Colitis Remission For 3 Years
21 Feb 2026 //
PR NEWSWIRE
Rybrevant Faspro Earns FDA Breakthrough Therapy Designation
19 Feb 2026 //
PHARMIWEB
J&J Halts Enrollment in Trial of AC Immune Alzheimer`s drug
19 Feb 2026 //
FIERCE BIOTECH
J&J to invest $1 billion in new Pennsylvania plant
18 Feb 2026 //
REUTERS
The Biggest Potential Drug Launches Of 2026
06 Feb 2026 //
FIERCE PHARMA
Johnson & Johnson receives CHMP positive opinion for AKEEGA
30 Jan 2026 //
GLOBENEWSWIRE
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication
28 Jan 2026 //
PR NEWSWIRE
Resolve M Therapeutics Exits From Stealth
22 Jan 2026 //
PHARMIWEB
Genmab Announces Net Sales Of DARZALEX (Daratumumab) For 2025
21 Jan 2026 //
GLOBENEWSWIRE
New Data Spotlights CAPLYTA For Remission in MDD Disorder
16 Jan 2026 //
PR NEWSWIRE
TECVAYLI Surpasses Standard of Care in R/R Multiple Myeloma
14 Jan 2026 //
PR NEWSWIRE
RYBREVANT Shows Promising, Durable Responses in Colorectal Cancer
10 Jan 2026 //
PR NEWSWIRE
Lexeo, J&J Team Up On Heart Pump Tech For Gene Therapy Delivery
08 Jan 2026 //
GLOBENEWSWIRE
J&J, Google Venture Arms Line Up To Back Epibiologics` Series B
08 Jan 2026 //
FIERCE BIOTECH
Bayer Sues Moderna, J&J And Pfizer/Biontech Over COVID Vax Tech
07 Jan 2026 //
FIERCE PHARMA
J&J Submits EMA Application for TECVAYLI Combo in Myeloma
06 Jan 2026 //
GLOBENEWSWIRE
Johnson & Johnson Reveals Nipocalimab As First FcRn Blocker
06 Jan 2026 //
PR NEWSWIRE
Johnson & Johnson Completes Acquisition of Halda Therapeutics
29 Dec 2025 //
BUSINESSWIRE
FDA Approves RYBREVANT + LAZCLUZE for Shortest First-Line Dosing
17 Dec 2025 //
PR NEWSWIRE
Link Cell Therapies Launches CAR-T for Solid, Liquid Tumors
15 Dec 2025 //
PR NEWSWIRE
FDA Approves AKEEGA For BRCA2-Mutated Prostate Cancer
12 Dec 2025 //
PR NEWSWIRE
Majestec-3 Study Backs TECVAYLI With DARZALEX FASPRO
09 Dec 2025 //
PR NEWSWIRE
NHS Scotland Approves RYBREVANT for EGFR+ NSCLC
09 Dec 2025 //
PHARMIWEB
ASH: J&J Pressures CAR-T With Tecvayli Combo In 2L Myeloma
09 Dec 2025 //
FIERCE PHARMA
Carvykti Shows Durable Remissions in Relapsed Multiple Myeloma
06 Dec 2025 //
GLOBENEWSWIRE
Johnson & Johnson`s INLEXZO Shows 74% Disease-Free Survival
05 Dec 2025 //
PR NEWSWIRE
Eisai Stays Confident In Anti-Tau Asset Amid J&J Setback In Tau
05 Dec 2025 //
BIOSPACE
J&J Wins EU Approval for IMAAVY in Generalized Myasthenia Gravis
01 Dec 2025 //
GLOBENEWSWIRE
ASH25: J&J`s Tecvayli, Darzalex Data May Shift Myeloma Paradigm
25 Nov 2025 //
BIOSPACE
J&J`s Anti-Tau Antibody Posdinemab Flops In Phase 2
24 Nov 2025 //
FIERCE BIOTECH
J&J discontinues Alzheimer`s study of tau-targeting antibody
21 Nov 2025 //
PRESS RELEASE
Contineum-J&J drug fails to improve vision in ph. 2 MS trial
20 Nov 2025 //
BUSINESSWIRE
Merus, Halozyme Sign Global Pact to Develop Petosemtamab
17 Nov 2025 //
PR NEWSWIRE
New Long-Term Data Reinforces TREMFYA Blocking Joint Damage
17 Nov 2025 //
PR NEWSWIRE
Halda Therapeutics Announces Acquisition By Johnson & Johnson
17 Nov 2025 //
PRESS RELEASE
J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T
12 Nov 2025 //
FIERCE PHARMA
EXoPERT Joins JLABS TMC, J&J`s Global Incubator Network
11 Nov 2025 //
PR NEWSWIRE
Samsung Bioepis Settles Pyzchiva (Ustekinumab) in Europe
06 Nov 2025 //
BUSINESS WIRE
J&J Secures First Expansion For Leading Cancer Drug
06 Nov 2025 //
PR NEWSWIRE
